EP3669007A1 - Souches de lactobacillus stimulant la croissance - Google Patents
Souches de lactobacillus stimulant la croissanceInfo
- Publication number
- EP3669007A1 EP3669007A1 EP18765960.2A EP18765960A EP3669007A1 EP 3669007 A1 EP3669007 A1 EP 3669007A1 EP 18765960 A EP18765960 A EP 18765960A EP 3669007 A1 EP3669007 A1 EP 3669007A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- strain
- subject
- lactobacillus plantarum
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Definitions
- Lactobacillus strains stimulate growth
- the present invention relates to novel bacterial strains capable of promoting the growth of a subject, and more particularly the juvenile growth of farmed animals, and their uses as probiotics. It also relates to food or pharmaceutical compositions comprising said strains, as well as their uses, in particular to increase the growth performance of farm animals.
- probiotics are "living microorganisms” , which, when ingested in sufficient quantities, have positive health effects, beyond the traditional nutritional effects ".
- Probiotics have been marketed and used in animal feed since the 1960s and have been the object of growing interest, particularly because of the gradual reduction in the use of antibiotics as growth promoters and their ban decreed in 2006 in Europe.
- microorganisms belong essentially to the bacteria of the genus Bacillus, Bifidobacterium, Enterococcus, Lactobacillus, Streptococcus and Pediococcus, and to the yeasts of the genus Saccharomyces or Kluyveromyces. Some of these microorganisms are usually part of the intestinal microbial community (or intestinal microbiota) while others are not usual hosts.
- this microbiota plays a key beneficial role for the host by exerting many biological functions, such as the aid to the efficiency of the digestion, the metabolism of the substrates, the fight against the pathogens, or the establishment and homeostasis of immune responses.
- the use of probiotic strains thus makes it possible to influence the composition as well as the activity of this microbiota in order to reinforce its beneficial action.
- the inventors have identified new bacterial strains capable of stimulating particularly efficiently animal growth.
- the present invention relates to a strain of
- Lactobacillus plantarum selected from the group consisting of the strain Lactobacillus plantarum IGFLl deposited on July 19, 2017 at the CNCM (National Collection of Cultures of Microorganisms - Pasteur Institute) under the number 1-5217, and the strain Lactobacillus plantarum IGFL2 deposited on 19 July 2017 at the CNCM (National Collection of Cultures of Microorganisms - Pasteur Institute) under the number 1-5218.
- composition comprising a strain of Lactobacillus plantarum according to the invention, in particular a probiotic composition.
- composition according to the invention may be a food composition, preferably a food supplement or a food additive, or a pharmaceutical composition.
- the composition according to the invention comprises between 10 5 and 10 12 colony-forming cells of a strain of Lactobacillus plantarum according to the invention.
- the present invention also relates to a strain of Lactobacillus plantarum according to the invention for use as a medicament, as well as the use of a strain of Lactobacillus plantarum according to the invention to prepare a composition according to the invention. invention.
- the present invention relates to a strain of Lactobacillus plantarum or a composition according to the invention for use in the treatment of growth retardation in a subject. In another aspect, the present invention relates to a strain of Lactobacillus plantarum or a composition according to the invention for use to promote the growth of a subject.
- the present invention relates to a non-therapeutic use of a strain of Lactobacillus plantarum or a composition according to the invention for increasing the growth performance of an animal.
- the subject may be a human or an animal, preferably a farmed animal.
- the subject is a juvenile subject.
- the subject is poultry, in particular poultry at a prenatal stage, i.e. in-ovo.
- the subject may in particular be subjected to or have been subjected to a nutritional deficiency, preferably a protein deficiency.
- Figure 1 Quantification of the promoter activity of animal growth of Lactobacillus plantarum strains. Size data are plotted totals with minimum and maximum values, median and 50 percentiles around the median.
- the present invention relates to a Lactobacillus strain capable of particularly efficiently stimulating growth, particularly skeletal growth, of a subject to which it is administered.
- the term "subject" refers to a human or animal.
- the subject may be a subject at a prenatal stage (embryo or fetus), a juvenile subject, that is to say a prepubertal human (from birth to puberty) or a weaned animal that has not reached maturity sexual, or an adult.
- the human subject is a prepubescent human or an adult.
- the animal can be in particular a pet, breeding or sport.
- the animal is selected from dogs, cats, cattle, sheep, rabbits, pigs, goats, equines, rodents, non-human primates and poultry.
- the subject is a farm animal, preferably selected from cattle, sheep, rabbits, pigs, goats, equines and poultry.
- the subject is a poultry.
- the subject is a subject at a prenatal stage (embryo or fetus) or a juvenile subject.
- the subject is a juvenile subject.
- the subject is a poultry at a prenatal stage.
- the subject has or has been subjected to nutritional deficiency, and in particular protein deficiency.
- the strains according to the invention have proved particularly suitable for promoting the growth, and especially the juvenile growth, of such subjects.
- These subjects can be identified by a weight, size and / or serum level of IGF-1 or similar growth factor in the target species, lower than those found in subjects of the same species, same age and same sex, and subject to a non-deficient diet.
- the term “growth” refers to weight gain and / or skeletal growth (also called linear growth in the case where the animal lacks a skeleton, for example in Drosophila) of a topic.
- the skeletal growth of a subject can be easily assessed by measuring, over a given period, the size of the individuals and / or the size of their bones, in particular their femurs.
- the term “growth” refers to the skeletal (or linear) growth of a subject.
- the effect of a strain of microorganism on the growth of a subject can be evaluated by any method known to those skilled in the art, and in particular by the methods described in the international patent application WO 2015/173386.
- the effect of a strain can be evaluated by a linear growth test of Drosophila melanogaster larvae.
- Drosophila larvae preferably axenic that is to say devoid of intestinal flora
- a nutritional medium supplemented with a suspension of the strain to be tested.
- the larvae are incubated for several days, for example 7 days, before measuring their phenotypic characteristics, namely their weight and / or size.
- the results obtained can then be compared with the results obtained with larvae incubated on a nutritional medium in the absence of a microbial strain. Strains for which weight gain and / or size gain is significantly greater than that obtained in the absence of a microbial strain are considered to have an effect on growth.
- strains exhibiting a significant positive effect preferably with a p-value less than or equal to 0.01 in the non-parametric Mann-Whitney or Kruskal-Wallis statistical test
- the results obtained can be compared to the results obtained with larvae incubated on a nutritional medium in the presence of a reference strain whose positive effect on growth is known.
- the selected strains may be those having an effect equivalent to or greater than the reference strain.
- Conventional nutritional media used in the laboratory generally include at least a vegetable meal, typically corn, inactivated yeasts, typically Saccharomyces cerevisiae, agar and water.
- the medium may be a deficient medium, that is to say a reduced content of inactivated yeasts. This deficient medium does not allow the optimal post-embryonic (ie, juvenile) development of Drosophila larvae (Storelli et al., Cell Metabolism 14, 403-414, 2011) and can therefore be used to test capacity. strains to stimulate growth in nutritional deficiency condition.
- the present invention therefore relates to a strain of Lactobacillus plantarum selected from the group consisting of the strain Lactobacillus plantarum IGFL1 deposited on July 19, 2017 at the CNCM (National Collection of Cultures of Microorganisms - Institut Pasteur) under the number 1-5217, and the strain Lactobacillus plantarum IGFL2 deposited on July 19, 2017 at the CNCM (National Collection of Cultures of Microorganisms - Institut Pasteur) under the number 1-5218.
- CNCM National Collection of Cultures of Microorganisms - Institut Pasteur
- the strain of Lactobacillus plantarum is the strain Lactobacillus plantarum IGFL 1.
- the present invention also relates to any bacterium derived from a strain of Lactobacillus plantarum according to the invention, in particular the bacteria derived from a strain of Lactobacillus plantarum according to the invention and having genetic modifications introduced naturally during divisions. cell phones or through the use of genetic engineering tools.
- the bacteria originating from a strain of Lactobacillus plantarum according to the invention have an effect on the growth of a subject at least equivalent to that of the strain Lactobacillus plantarum IGFL1 or IGFL2, preferably that of the strain Lactobacillus plantarum. IGFL1.
- This effect on growth can be evaluated by any method known to those skilled in the art, more particularly by a test on the linear growth of Drosophila melanogaster larvae as detailed above or in the experimental part.
- the present invention relates to a composition comprising a strain of Lactobacillus plantarum according to the invention. It also relates to the use of a strain of Lactobacillus plantarum according to the invention for the preparation of a composition according to the invention. It relates more particularly to the use of a strain of Lactobacillus plantarum according to the invention as a probiotic.
- composition according to the invention may comprise one or more strains according to the invention, namely Lactobacillus plantarum IGFL1, Lactobacillus plantarum IGFL2 or a mixture of Lactobacillus plantarum IGFL1 and Lactobacillus plantarum IGFL2.
- the composition may also include one or more additional strains of microorganisms, including microorganisms used as probiotics.
- the composition may comprise one or more additional microorganism strains selected from the group consisting of Bacillus, Bifidobacterium, Enter ococcus, Streptococcus, Pediococcus, Saccharomyces, Kluyveromyces, and / or Lactobacillus such as Lactobacillus delbrueckii, Lactobacillus plantarum, Lactobacillus fermentum , Lactobacillus casei, Lactobacillus paracasei, Lactobacillus rhamnosus.
- the composition may comprise one or more additional Lactobacillus strains selected from the group consisting of L. plantarum WJL (Kim et al., Genome Announc, November 21, 2013), L. plantarum G821 (deposited at the CNCM under the number CNCM 1-4979 May 11, 2015), L. plantarum NIZO 2877, L. casei ATCC 393, L. casei L919 (Koryszewska-Baginska A et al., Genome Announc, 26 September 2013), L. paracasei ATCC 25302, L. paracasei Shirota (Yuki N et al., Int J Food Microbiol, Apr. 1, 1999, 48 (1): 51-7), L.
- L. plantarum WJL Kim et al., Genome Announc, November 21, 2013
- L. plantarum G821 deposited at the CNCM under the number CNCM 1-4979 May 11, 2015
- L. plantarum NIZO 2877 L. casei
- the composition comprises one or more additional strains of Lactobacillus plantarum, preferably selected from the group consisting of L. plantarum WJL, L. plantarum G821 and L. plantarum NIZO 2877.
- the strains or strains contained in the composition can be alive or inactivated.
- the strains or strains contained in the composition are in living form. They can in particular be in a hydrated form, freeze-dried, frozen or any other form allowing them to be administered alive to the subject.
- the strains are in lyophilized form, these can be administered as such or after recovery in a suitable vehicle, for example in water or any other beverage.
- a suitable vehicle for example in water or any other beverage.
- the strains are in frozen form, they are preferably thawed before administration.
- the composition according to the invention is preferably a probiotic composition.
- probiotic composition refers to a composition comprising one or more strains of probiotic microorganisms, i.e., one or more living strains which, when administered to the subject, preferably orally, exert at least one positive effect on the health of the subject, for example stimulates its growth. When several probiotic strains are used, these may have similar or different effects.
- the composition according to the invention can comprise a strain according to the invention which has an effect on the growth of the subject and another strain of microorganism which has a stimulating effect on the immune system.
- composition according to the invention may be in any form adapted to its administration to the subject. According to some embodiments, the composition according to the invention is in a form suitable for oral or rectal administration. According to other embodiments, the composition according to the invention is in a form suitable for prenatal administration, in particular by in-ovo injection.
- the composition according to the invention may especially be in the form of powder, solids, semi-solid or liquid. Depending on the intended applications and the nature of the composition, it can thus be for example in the form of tablets, capsules, capsules, granules, powder, suspensions, emulsions, solutions or suppositories.
- the composition is in a gastro-resistant oral form allowing the bacteria contained in the composition, and more particularly the bacteria according to the invention, to pass the stomach and be released into the intestine.
- composition according to the invention is preferably a food or pharmaceutical composition.
- the composition according to the invention is a food composition.
- the term "food composition” includes any non-pharmaceutical composition for administration / use / consumption by a subject orally.
- the composition may be for human or animal consumption.
- These compositions may in particular be food additives, food supplements, solid or liquid foods, in particular juices or dairy products such as milk drinks, yogurts, cheeses or ice creams.
- the composition according to the invention is a food additive or a food supplement.
- the term "food additive” refers to a composition that is intended to be mixed with one or more other foods before being administered to a subject. More particularly, the composition according to the invention may be a probiotic food additive, in particular a probiotic additive as authorized by European Directive 70/524 / EC or Regulation 1831/2003 / EC.
- the term "dietary supplement” refers to a composition that is formulated and administered separately from other foods and is intended to complement a subject's nutritional intake. According to a particular embodiment, the composition according to the invention is a food, food supplement or food additive for animal feed, and more particularly for feeding farm animals.
- the composition according to the invention is a pharmaceutical composition. It may be intended for use in human medicine or veterinary use.
- the pharmaceutical composition according to the invention is a composition intended for administration orally, rectally or to prenatal administration, more particularly by injection in-ovo.
- the pharmaceutical composition according to the invention is a composition intended for oral administration.
- the pharmaceutical composition according to the invention is a composition intended for prenatal administration, more particularly by injection in-ovo.
- the pharmaceutical composition according to the invention may comprise any excipient and / or pharmaceutically acceptable vehicle, in particular any excipient and / or vehicle suitable for administration by the oral route or by injection in-ovo.
- the pharmaceutically acceptable excipients and carriers that can be used are well known to those skilled in the art (e.g., Remington's Pharmaceutical Sciences, 18 th edition, AR Gennaro, Ed., Mack Publishing Company [1990], Pharmaceutical Formulation Development of peptides and Proteins, S. and L. Fr ⁇ kj ⁇ r Hovgaard, Eds, Taylor & Francis, [2000]. and Handbook of Pharmaceutical Excipients, 3rd edition, A. Kibbe, Ed, Pharmaceutical Press, [2000]).
- the composition according to the invention preferably contains between 10 5 to 10 12 , in particular from 10 6 to 10 12 , preferably from 10 8 to 10 12 colony forming cells (CFU), preferably cells of a strain according to the invention. invention, per gram of composition.
- CFU colony forming cells
- Per gram of composition is preferably meant the composition according to the invention comprising the bacteria according to the invention, and the appropriate co-ingredients, excipients or vehicles.
- the co-ingredients may include foods and / or other microorganism strains.
- the present invention also relates to a strain of Lactobacillus plantarum according to the invention for use as a medicament. It relates in particular to a pharmaceutical composition comprising a strain of Lactobacillus plantarum according to the invention as an active ingredient.
- the pharmaceutical composition may be as defined above.
- the present invention also relates to
- a method of treating a growth retardation in a subject comprising administering a therapeutically effective amount of a strain of Lactobacillus plantarum according to the invention or of a composition according to the invention, preferably a pharmaceutical composition , to the subject.
- the subject is a juvenile subject and the administration of the strain or the composition according to the invention is preferably done orally.
- the subject is at a prenatal stage, in particular a fowl at a prenatal stage, and the administration of the strain or composition according to the invention is by in-ovo injection.
- a subject with growth retardation can be identified by a weight, a size and / or a serum level of IGF-1 lower than those found in a subject of the same species, same age and same sex.
- This growth retardation can have various causes such as, for example, a nutritional deficiency, in particular a protein deficiency.
- This deficiency may be related to chronic or acute undernutrition, or pathophysiological undernutrition related to a pathological condition of the patient.
- This pathological condition can be a motor handicap, anorexia, a pathology of ingestion and / or assimilation, cachexia or sarcopenia.
- the present invention relates in particular to
- a strain of Lactobacillus plantarum or a composition according to the invention for a use intended to promote the growth of a subject, preferably a juvenile subject, subjected to or having been subjected to a nutritional deficiency, preferably a protein deficiency; the use of a strain of Lactobacillus plantarum according to the invention or of a composition according to the invention, for the preparation of a medicament intended to promote the growth of a subject, preferably a juvenile subject, subject or having been subjected to a nutritional deficiency, preferably a protein deficiency; and
- a method for promoting the growth of a subject preferably a juvenile subject, subject to or having been subjected to a nutritional deficiency, preferably a protein deficiency, comprising the administration of a sufficient amount of a Lactobacillus strain; plantarum according to the invention or a composition according to the invention, preferably a pharmaceutical composition, to said subject.
- said subject has a growth retardation induced by this nutritional deficiency.
- the therapeutically effective or sufficient amount of a strain of Lactobacillus plantarum according to the invention or of a composition according to the invention is a quantity making it possible to obtain the desired effect, namely a positive effect (an increase) on growth. from subject.
- the amount and frequency of administration will depend on the type of subject, human or animal, the age and physiological state of the subject including stunting and / or level of nutritional deficiency.
- the strain of Lactobacillus plantarum or the composition according to the invention can be administered in one or more times, that is to say in the form of a single dose or multiple doses.
- the strain or composition according to the invention may be administered in the form of several doses spread over the growth period of the subject, preferably until puberty or sexual maturity.
- the strain or composition according to the invention is administered to the subject at a frequency of between one dose per day and one dose per month.
- the frequency of administration is between one dose per day and one dose per week, in particular one dose every 2, 3, 4, 5, 6 or 7 days.
- the frequency of administration may be between several doses per day, for example 2, 3, 4 or 5 doses per day, and one dose per week.
- a dose may represent several grams to several tens of grams of composition according to the invention.
- a dose represents between 1 and 100 g of composition according to the invention, preferably between 1 and 50 g of composition according to the invention, and more particularly preferably between 1 and 10 g of composition. according to the invention.
- a dose may represent between 10 5 and 10 13 CFU, preferably between 10 6 and 10 12 CFU, of Lactobacillus plantarum according to the invention.
- daily doses may be divided to facilitate administration, for example with one administration in the morning and another in the evening.
- the present invention relates to the non-therapeutic use of a strain or composition according to the invention for increasing the growth performance of an animal. It also relates to a method for increasing the growth performance of an animal comprising the administration of a sufficient amount of a strain or a composition according to the invention to obtain a positive effect on the growth of the animal.
- This positive effect may result in particular in weight gain and / or an increase in the skeletal (or linear) growth of the animal greater than the weight gain or the skeletal growth (or linear growth) of the animal not treated with the strain. or composition according to the invention.
- the animal is a sport animal or farm animal, and more preferably a farm animal.
- the animal is a juvenile subject and the administration of the strain or composition according to the invention is preferably done orally.
- the strain or composition according to the invention is preferably administered to the animal at the same time as its normal diet.
- the composition according to the invention can be a food additive added to the feed of the animal or a veterinary dietary supplement.
- the subject is at a prenatal stage, in particular a fowl at a prenatal stage, and the administration of the strain or composition according to the invention is by in-ovo injection.
- Jl Axenic adult drosophila (D. melanogaster strain yw) were placed in laying cages with a bottom (Petri dish type) on which is placed a conventional nutritional medium (for 1 liter of medium, 7.14 g of agar, 80 g of corn flour and 50 g of inactivated yeast, the medium is cooked in boiling water for 10 minutes, then cooled); spawning is ensured by maintaining the adult population in the cage 1 night at 25 ° C.
- a conventional nutritional medium for 1 liter of medium, 7.14 g of agar, 80 g of corn flour and 50 g of inactivated yeast, the medium is cooked in boiling water for 10 minutes, then cooled
- spawning is ensured by maintaining the adult population in the cage 1 night at 25 ° C.
- D0 6 pieces of the nutritional medium were cut to collect 6 times 40 embryos. Each of these parts was placed on a nutrient medium contained in a petri dish (medium comprising 6g of inactivated yeast per liter instead of 50g per liter in conventional medium). Three plates were inoculated with a suspension of 10 8 CFUs (colony forming unit) of the bacterium to be tested in 1x PBS. Three other boxes (controls) were "inoculated” with sterile 1x PBS. These plates were incubated for 7 days at 25 ° C.
- J7 The larvae which developed were recovered from each box (the experiment being exploitable from 20 larvae per box, the groups used hereafter comprise more than 60 individuals). The larvae underwent shock heat treatment in order to sacrifice them (5 seconds on a plate heated to 100 ° C), before measuring the size of the larvae (linear measurement from the anterior end to the posterior end).
- Lactobacillus plantarum (IGFL1, IGFL2, NIZ02877, WJL and G821) comprising 3 strains previously described in the patent application WO 2015/173386 to have a more or less marked effect on the linear growth of Drosophila larvae, namely strains NIZ02877, WJL and G821).
- strains of Lactobacillus plantarum NIZ02877, WJL, G821, IGFL1 and IGFL2 all exhibit growth promoting activity in the in vivo growth test of Drosophila larvae.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1757717A FR3070167B1 (fr) | 2017-08-17 | 2017-08-17 | Souches de lactobacillus stimulant la croissance |
PCT/FR2018/052070 WO2019034826A1 (fr) | 2017-08-17 | 2018-08-17 | Souches de lactobacillus stimulant la croissance |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3669007A1 true EP3669007A1 (fr) | 2020-06-24 |
Family
ID=61132473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18765960.2A Pending EP3669007A1 (fr) | 2017-08-17 | 2018-08-17 | Souches de lactobacillus stimulant la croissance |
Country Status (6)
Country | Link |
---|---|
US (1) | US11497779B2 (fr) |
EP (1) | EP3669007A1 (fr) |
CN (1) | CN111212902B (fr) |
CA (1) | CA3073105A1 (fr) |
FR (1) | FR3070167B1 (fr) |
WO (1) | WO2019034826A1 (fr) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120034199A1 (en) | 2009-04-09 | 2012-02-09 | Teck Chwen Loh | Monogastric animal feed |
MX338680B (es) * | 2009-05-11 | 2016-04-27 | Nestec Sa | Bifidobacterium longum ncc2705 (cncm i-2618) y padecimientos inmunes. |
MY175316A (en) * | 2011-01-25 | 2020-06-19 | Austrianova Singapore Pte Ltd | Protection of microbial cells from acidic degradation |
GB201102857D0 (en) * | 2011-02-18 | 2011-04-06 | Danisco | Feed additive composition |
FR3020949B1 (fr) * | 2014-05-16 | 2018-02-09 | Ecole Normale Superieure De Lyon | Composition permettant de favoriser la croissance juvenile humaine et animale en cas de malnutrition |
-
2017
- 2017-08-17 FR FR1757717A patent/FR3070167B1/fr active Active
-
2018
- 2018-08-17 CN CN201880064039.6A patent/CN111212902B/zh active Active
- 2018-08-17 US US16/639,277 patent/US11497779B2/en active Active
- 2018-08-17 EP EP18765960.2A patent/EP3669007A1/fr active Pending
- 2018-08-17 CA CA3073105A patent/CA3073105A1/fr active Pending
- 2018-08-17 WO PCT/FR2018/052070 patent/WO2019034826A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CA3073105A1 (fr) | 2019-02-21 |
WO2019034826A1 (fr) | 2019-02-21 |
US11497779B2 (en) | 2022-11-15 |
FR3070167A1 (fr) | 2019-02-22 |
FR3070167B1 (fr) | 2021-12-24 |
CN111212902B (zh) | 2023-04-04 |
US20200246400A1 (en) | 2020-08-06 |
CN111212902A (zh) | 2020-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110835616B (zh) | 副干酪乳杆菌gks6的活性物质、含其的组合物及其促进长寿的用途 | |
CA2709850C (fr) | Composition pour l'alimentation humaine et/ou animale, ses utilisations, levures | |
EP3164144B1 (fr) | Composition de lactobacillus permettant de favoriser la croissance juvenile humaine et animale en cas de malnutrition | |
JP2010143885A (ja) | 乳酸菌およびそれらを用いた飲食物又は化粧品 | |
EP2931289B1 (fr) | Chitine ou ses derives pour la prevention et/ou le traitement de parasitoses | |
KR20190055552A (ko) | 피부 미백 및 보습개선 활성을 갖는 락토바실러스 플란타럼 WiKim0060 및 이를 포함하는 조성물 | |
KR20190133639A (ko) | 락토바실러스 크리스파투스 kbl693 균주 및 그 용도 | |
CN110833565B (zh) | 植物乳杆菌gkm3的活性物质、含其的组合物及其促进长寿的用途 | |
CA2794463A1 (fr) | Utilisation d'un produit de fermentation fongique comme complement alimentaire | |
EP4181938A1 (fr) | Combinaison de souches de lactobacilles et son utilisation en sante animale | |
KR101992331B1 (ko) | 피부 미백 및 보습개선 활성을 갖는 류코노스톡 시트리움 WiKim0059 및 이를 포함하는 조성물 | |
WO2014181249A1 (fr) | Acide pétrosélinique ou association d'actifs comprenant au moins l'acide pétrosélinique pour favoriser la perte de poids et/ou le maintien du poids | |
TW201609120A (zh) | 含乳酸菌之腸道屏障功能促進劑 | |
WO2023088591A1 (fr) | Souche bactérienne et utilisation de celle-ci | |
EP3669007A1 (fr) | Souches de lactobacillus stimulant la croissance | |
CA3198168A1 (fr) | Composition symbiotique comme additif d'alimentation pour les porcelets ou les truies et son utilisation | |
KR20180110848A (ko) | 신규한 락토바실러스 루테리 균주 및 그 프로바이오틱 용도 | |
EP0863763B1 (fr) | Utilisation d'une preparation deshydratee de bacteries propioniques pour la preparation d'une composition dietetique susceptible d'ameliorer l'equilibre biologique de la flore du tractus intestinal | |
CA2530631C (fr) | Utilisation de bacteries de la classe des bacilli pour la fabrication d'une composition pour la prevention du syndrome de compression des vertebres chez les salmonides | |
WO2018104336A1 (fr) | Bactéries lactiques utiles pour traiter les maladies métaboliques, notamment le diabète de type 2 | |
JP6487106B1 (ja) | 免疫機能向上用食品組成物 | |
EP3413724A1 (fr) | Composition probiotique permettant de favoriser la croissance juvénile de l'animal d'élevage | |
WO2024105265A1 (fr) | Limosilactobacillus mucosae et désordres nécessitant un accroissement du niveau de glp-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200311 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230503 |